(Press-News.org) The experimental heart failure drug omecamtiv mecarbil reduced heart failure hospitalizations by a greater margin among patients with more severely reduced ejection fraction, a measure indicating severe impairment in the heart's pumping ability, compared with those who had moderately reduced ejection fraction, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.
Omecamtiv mecarbil works by improving the ability for heart muscle cells to contract and operates through a different biological pathway than any of the current heart failure medications. The research is an extended analysis of data from GALACTIC-HF, a trial involving more than 8,200 participants that found omecamtiv mecarbil significantly improved outcomes in terms of a composite of cardiovascular death or heart failure events among patients with heart failure with reduced ejection fraction. The new analysis focused on how patient outcomes varied based on the level of severity of their reduced ejection fraction.
"This is a drug that will potentially help the very group of patients that are most difficult to care for," said John R. Teerlink, MD, a cardiologist at the University of California, San Francisco and the San Francisco VA Medical Center, and the study's lead author. "While the results from GALACTIC-HF show omecamtiv mecarbil brought improvements overall, these new findings point to a group of patients with more severe heart failure in whom there is even greater benefit."
Heart failure is a condition in which the heart becomes too weak to pump blood effectively to the rest of the body. The trial investigated omecamtiv mecarbil in patients with heart failure with an ejection fraction of less than or equal to 35%. Ejection fraction is a measure of the amount of oxygen-rich blood that the heart pushes out with each heartbeat (50-70% is considered normal).
As previously reported, the GALACTIC-HF trial met its primary endpoint, which was a composite of time to first heart failure event or death due to cardiovascular causes, and the benefit was predominantly driven by reductions in heart failure events, with no significant improvement in the rate of death from cardiovascular causes compared to placebo. An additional benefit, according to Teerlink, is that when compared with other commonly used heart failure medications, omecamtiv mecarbil did not adversely affect blood pressure, heart rate, potassium concentrations or renal function, even when used alongside current heart failure medications. In addition, there was no increase in cardiac ischemic or ventricular arrhythmic events.
"The good news is omecamtiv mecarbil can be added on to a patient's treatment regimen at any time, because it doesn't interact with any of the commonly used heart failure therapies in terms of adverse effects," Teerlink said. "While it doesn't provide a benefit in terms of reducing cardiovascular death, it can provide its benefit in terms of reducing heart failure hospitalizations virtually anywhere in the treatment process."
In the new analysis, researchers found that the relative and absolute benefits from omecamtiv mecarbil significantly improved with progressively lower ejection fraction. Patients in the two lowest quartiles in terms of ejection fraction had a 15-17% reduction in the risk of dying from cardiovascular causes or being hospitalized with heart failure, compared to 8% for the entire patient population. In the lowest quartile, the absolute risk reduction was 7.4 per 100 patient years, meaning that treating fewer than 12 patients with omecamtiv mecarbil would result in preventing one cardiovascular death or heart failure hospitalization.
"That's a very important and clinically meaningful finding, particularly given that patients with low ejection fraction tend to be at the highest risk and the hardest to treat," Teerlink said.
The study did not show a clear benefit of omecamtiv mecarbil among patients with ejection fraction higher than about 30%. The researchers plan to further investigate this finding to determine whether a subset of these patients may benefit from the therapy. Additional studies are underway to examine whether having atrial fibrillation or other conditions in addition to heart failure may affect outcomes from the drug.
INFORMATION:
This study was simultaneously published online in the Journal of the American College of Cardiology at the time of presentation. The study was funded by Amgen, Cytokinetics, Inc. and Servier.
Teerlink will be available to the media in a virtual press conference on Monday, May 17, at 9:30 a.m. ET / 13:30 UTC.
Teerlink will present the study, "Impact of Ejection Fraction on the Therapeutic Effect of Omecamtiv Mecarbil in Patients with Heart Failure and Reduced Ejection Fraction: A Secondary Analysis from GALACTIC-HF," on Monday, May 17, at 8 a.m. ET / 12:00 UTC, virtually.
ACC.21 will take place May 15-17 virtually, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC21 for the latest news from the meeting.
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit ACC.org.
Media Contacts
Nicole Napoli
202-669-1465
nnapoli@acc.org
Thy-Ann Nguyen
703-479-3642
thyann.nguyen@curastrategies.com
One of the enduring mysteries of the COVID-19 pandemic is why most children tend to experience fewer symptoms than adults after infection with the coronavirus. The immune system response that occurs in the rare cases in which children experience life-threatening reactions after infection may offer an important insight, a Yale-led study published in the journal Immunity suggests.
While many children infected with the virus are asymptomatic or go undiagnosed, about one in 1,000 children experience multi-system inflammatory response (MIS-C) four to six weeks after confirmed infection with SARS-CoV-2, the virus that causes COVID-19. The condition ...
Inserm teams led by Laurent Reber (Infinity, Toulouse) and Pierre Bruhns (Humoral Immunity, Institut Pasteur, Paris) and French company NEOVACS have developed a vaccine that could induce long-term protection against allergic asthma, reducing the severity of its symptoms and thus significantly improving patient quality of life. Their research in animals has been published in the journal Nature Communications.
Asthma is a chronic disease affecting around 4 million people in France and 340 million worldwide. Allergic asthma is characterized by inflammation of the bronchial tubes and respiratory discomfort caused by the inhalation of allergens, most often dust mites. This exposure to dust mites and other allergens leads to ...
A randomized double-blind controlled trial of convalescent plasma for adults hospitalized with severe COVID-19 found that mortality at 28 days in the treatment arm was half the rate seen in the control arm (12.6% vs. 24.6%), although treatment was not associated with other improvements in clinical status.
The study was led by investigators from the Center for Infection and Immunity at Columbia University Mailman School of Public Health; Columbia University Irving Medical Center; ICAP at Columbia University; Instituto Nacional de Infectologia and Hospital Federal dos Servidores do Estado in Rio de Janeiro, Brazil; University of Washington; and New York Blood Center. The results are published in the Journal of Clinical Investigation.
According ...
Patients with heart failure with preserved ejection fraction who took the antifibrotic drug pirfenidone saw a significant reduction in a marker of heart muscle scarring compared with patients who received a placebo, based on findings from an early-phase trial presented at the American College of Cardiology's 70th Annual Scientific Session.
"Observational data suggests that heart muscle scarring, or fibrosis, is an important disease process for heart failure prognosis," said Chris Miller, MD, a cardiologist and National Institute for Health Research Clinician Scientist at the University ...
Patients with heart failure with reduced ejection fraction (HFrEF) did not have better health outcomes if they took sacubitril/valsartan combination therapy compared with valsartan alone, according to new data presented at the American College of Cardiology's 70th Annual Scientific Session.
Heart failure, a leading cause of hospitalization among adults over age 65, is a condition in which the heart becomes too weak to pump blood effectively to the rest of the body, causing fatigue and shortness of breath. For patients with severe heart failure, treatment options are limited to a mechanical heart pump or heart transplant. Doctors have sought ways to slow the progression of severe heart failure ...
The likelihood of people surviving COVID-19 in UK hospitals has been improving over time, a new study has found.
Research published in The Lancet Respiratory Medicine by the ISARIC Coronavirus Clinical Characterisation Consortium found that in-hospital mortality declined from 32% at the start of the first wave (Mar-Apr 2020) to 16% at the end of the first wave (Jun-Jul 2020).
In their study of 63,972 adults admitted to 247 UK hospitals the researchers found reductions in mortality were observed in all age groups, in all ethnic groups, for both sexes, and in patients with and without comorbidities. This improvement was ...
A group of Brazilian and Portuguese researchers observed a correlation between the presence of lead in the organism and a microRNA (miRNA) that could be associated with the mechanisms that regulate DNA methylation, a physiological process required to control gene expression and ensure that genes function properly.
The alterations were detected in blood cells from workers in automotive battery plants, which use lead as a raw material. Curiously, lead levels in blood samples from 85 volunteers – averaging 20 micrograms per deciliter of blood (20 μg/dl) – were lower than the acceptable ceiling defined in Brazilian law (60 μg/dl).
The study was supported by FAPESP and ...
A long noncoding RNA whose function was previously unknown turns out to play an important role in promoting the body's immune response against cancer and holds promise for enhancing the efficacy of anti-cancer immunotherapy.
That's according to new findings reported in Nature Cell Biology by researchers at the University of Michigan Rogel Cancer Center.
The group dubbed the RNA they identified LIMIT -- for long noncoding RNA inducing major histocompatibility complex class I and immunogenicity of tumor.
"LIMIT is easy to remember, but really it does the opposite. It stimulates immune functions against cancer," says senior study author Weiping Zou, M.D., Ph.D., the Charles B. de Nancrede Professor of Pathology, Immunology, Biology, and Surgery at U-M.
Only a small part of the human ...
Researchers at the University of California, Davis, have found a link between traffic-related air pollution and an increased risk for age-related dementia, including Alzheimer's disease. Their study, based on rodent models, corroborates previous epidemiological evidence showing this association.
Alzheimer's disease is the most common cause of age-related dementia and the sixth leading cause of death in the United States. More than 5 million Americans currently live with Alzheimer's disease -- a number that is expected to triple by 2050 as the population ages. ...
In patients receiving therapeutic hypothermia after suffering out-of-hospital cardiac arrest, those who were cooled below 31 degrees Celsius (about 88 degrees Fahrenheit) for 24 hours showed no difference in terms of death or poor neurological outcomes at six months compared with patients receiving guideline-recommended cooling of 34 C (about 93 F). These findings are part of a study presented at the American College of Cardiology's 70th Annual Scientific Session.
Therapeutic hypothermia is a procedure in which a person's body is cooled far below normal body temperature. It has been shown to improve survival and reduce brain damage in people who have been resuscitated but remain comatose after suffering cardiac arrest (when the heart stops ...
